Histogenics signs merger agreement with Ocugen

Gunderson Dettmer client Histogenics, a developer of restorative cell therapies for pain management, has entered into a definitive merger agreement with Ocugen, a privately held pharmaceutical company targeting rare and underserved eye diseases, to create a publicly-traded clinical-stage biopharmaceutical company. The merged company will operate under the name Ocugen.

The Gunderson Dettmer deal team included Marc Dupre, Albert Vanderlaan, Keith Scherer, Daniel Riley and Samantha Gross.